Klinische Studie NCT04613596 · Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
NCT04613596 — ist «rekrutierend» auf ClinicalTrials.gov.
Klinische Studie NCT04613596 (Phase II/III) ist «rekrutierend» auf ClinicalTrials.gov.
Erkrankung: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer · Registrierte Interventionen: Adagrasib, Pembrolizumab · Erfasste Daten (Quelle): 2020-12-02, 2028-10-31, 2020-11-03, 2026-10-30.
Studienzusammenfassung (Quelle: ClinicalTrials.gov, Originaltext auf Englisch):
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.
The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.